arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Aptevo Therapeutics Inc.

APVO
$4.19 ▲ +0.19 (+4.75%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
44 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
22
Health
Poor
Bearish
auto_awesome

Analytical Summary

Aptevo Therapeutics Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $4.4M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -46.5%
FCF / Share $-7.51
Trailing P/E
Price / Book 0.4x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

44-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-6.70M
↓ -4.5%
Operating Margin Operating profit as % of sales
-180.2%
↓ -63.5%
FCF / Share Free cash flow per share
$-7.51
↑ +72.7%
Long-Term Debt Long-term obligations
$0.00
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
5
Cash Quality
65

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 12 years · 44 quarters